Tiotropium / Respimat One-Year Study
Public ClinicalTrials.gov record NCT00168831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
Study identification
- NCT ID
- NCT00168831
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,007 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2003
- Primary completion
- May 31, 2005
- Completion
- Not listed
- Last update posted
- May 19, 2014
Started 2003
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| Boehringer Ingelheim Investigational Site | San Luis Obispo | California | — | — |
| Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Hallandale | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Hines | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| Boehringer Ingelheim Investigational Site | Bay Shore | New York | — | — |
| Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00168831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2014 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00168831 live on ClinicalTrials.gov.